Logo

American Heart Association

  1
  0


Final ID: WP186

Small Vessel Disease is Associated With Primary Aldosteronism in Acute Ischemic Stroke

Abstract Body: Background and Purpose: Primary aldosteronism (PA) is characterized by the autonomous overproduction of aldosterone leading to the risk of occurrence of acute ischemic stroke (AIS), but the exact prevalence of PA is unknown in patients with AIS. PA induces oxidative stress and inflammation through vascular endothelial cells, which may damage small vessel disease (SVD). We conducted a prospective study to investigate the prevalence of screening and definite diagnosis of PA in patients with AIS. Next, we aimed to reveal whether SVD markers could be associated with PA.
Methods: We screened consecutive patients with AIS who participated in our prospective study to investigate the prevalence of PA and followed up for PA evaluation from October 2020 to December 2022. Inclusion criteria were patients with AIS hospitalized and diagnosed with hypertension. Exclusion criteria were patients taking medications affecting renin, aldosterone, and catecholamines. The screening criteria for PA was defined as the aldosterone-to-renin ratio > 200. Final diagnosis of PA was judged by endocrinologist if one of the captopril challenge test, saline infusion test, and furosemide-upright test was positive following discharge. We evaluated total SVD score based on white matter hyperintensities (separately scored by periventricular hyperintensity [PVH] and deep and subcortical white matter hyperintensity), cerebral microbleeds (CMBs; categorized into deep, lobar, and infratentorial lesions), enlarged perivascular spaces (separately scored in basal ganglia and centrum semiovale), and old lacunes on MRI.
Results: We included 120 patients with AIS (93 [78%] male, median age 62 years, Figure 1). The screening for PA was positive in 33 (28%) patients and 8 (7%) patients were finally diagnosed with definite PA. In Poisson regression analysis with a robust variance estimator, total SVD score was related to positive PA screening (prevalence ratio [PR] 1.261, 95% CI 1.021-1.556, p = 0.031) and definite PA diagnosis (PR 1.946, 95% CI 1.229-3.082, p = 0.005, Figure 2). In terms of each SVD marker, severe PVH, and deep and lobar CMBs were associated with positive PA screening and definite PA diagnosis (Figure 3).
Conclusions: Twenty-eight percent of patients with AIS were positive for PA screening, and then about a quarter of them were confirmed as definite PA. SVD burden, especially PVH, and deep and lobar CMBs, might be associated with positive screening and definite diagnosis of PA.
  • Okumura, Motohiro  ( The Jikei University School of Medicine , Tokyo , Japan )
  • Komatsu, Teppei  ( The Jikei University School of Medicine , Tokyo , Japan )
  • Sakuta, Kenichi  ( The Jikei University School of Medicine , Tokyo , Japan )
  • Sakai, Kenichiro  ( The Jikei University School of Medicine , Tokyo , Japan )
  • Mitsumura, Hidetaka  ( The Jikei University School of Medicine , Tokyo , Japan )
  • Nishimura, Rimei  ( The Jikei University School of Medicine , Tokyo , Japan )
  • Iguchi, Yasuyuki  ( The Jikei University School of Medicine , Tokyo , Japan )
  • Sato, Takeo  ( The Jikei University School of Medicine , Tokyo , Japan )
  • Tsujimoto, Yuki  ( The Jikei University School of Medicine , Tokyo , Japan )
  • Yamashiro, Kenji  ( The Jikei University School of Medicine , Tokyo , Japan )
  • Watanabe, Yui  ( The Jikei University School of Medicine , Tokyo , Japan )
  • Kida, Hiroyuki  ( The Jikei University School of Medicine , Tokyo , Japan )
  • Nakada, Ryoji  ( The Jikei University Kashiwa Hospital , Kashiwa-shi , Japan )
  • Kitagawa, Tomomichi  ( The Jikei University School of Medicine , Tokyo , Japan )
  • Takatsu, Hiroki  ( The Jikei University School of Medicine , Tokyo , Japan )
  • Author Disclosures:
    Motohiro Okumura: DO NOT have relevant financial relationships | Teppei Komatsu: DO NOT have relevant financial relationships | Kenichi Sakuta: DO NOT have relevant financial relationships | Kenichiro Sakai: DO NOT have relevant financial relationships | Hidetaka Mitsumura: DO NOT have relevant financial relationships | Rimei Nishimura: DO have relevant financial relationships ; Speaker:Sanofi Co., Ltd:Active (exists now) ; Research Funding (PI or named investigator):Arkley:Active (exists now) ; Research Funding (PI or named investigator):KOWA:Active (exists now) ; Consultant:Medtronic Co., Ltd:Active (exists now) ; Consultant:Abbott:Active (exists now) ; Consultant:Novo Nordisk Pharma Co., Ltd:Active (exists now) ; Consultant:Eli Lilly Japan Co., Ltd:Active (exists now) ; Speaker:Teijin:Active (exists now) ; Speaker:Nippon Boehringer Ingelheim Co., Ltd:Active (exists now) | Yasuyuki Iguchi: DO have relevant financial relationships ; Speaker:Daiichi-Sankyo:Active (exists now) ; Speaker:Alexion:Active (exists now) ; Speaker:Amagen Biogen:Active (exists now) ; Speaker:Takeda:Active (exists now) ; Speaker:Sumitomo Dainippon:Active (exists now) ; Speaker:Pfizer:Active (exists now) ; Speaker:Otsuka:Active (exists now) ; Speaker:Novartis:Active (exists now) ; Speaker:Mitsubishi-Tanabe:Active (exists now) ; Speaker:JB:Active (exists now) ; Speaker:Eisai:Active (exists now) ; Speaker:CSL-Behring:Active (exists now) ; Speaker:Chugai:Active (exists now) | Takeo Sato: DO NOT have relevant financial relationships | Yuki Tsujimoto: DO NOT have relevant financial relationships | Kenji Yamashiro: DO have relevant financial relationships ; Research Funding (PI or named investigator):Teijin Pharma Ltd.:Past (completed) ; Research Funding (PI or named investigator):Ono Pharmaceutical Co., Ltd.:Past (completed) | Yui Watanabe: DO NOT have relevant financial relationships | Hiroyuki Kida: DO NOT have relevant financial relationships | Ryoji Nakada: DO NOT have relevant financial relationships | Tomomichi Kitagawa: DO NOT have relevant financial relationships | Hiroki Takatsu: DO NOT have relevant financial relationships
Meeting Info:
Session Info:

Imaging Posters I

Wednesday, 02/05/2025 , 07:00PM - 07:30PM

Poster Abstract Session

More abstracts on this topic:
A Randomized, Double Blinded, Phase 2B Clinical Trial to Compare the Safety and Efficacy of Sodium Chloride and Sodium Acetate Combination Intravenous Fluids in Acute Stroke Patients

Wasay Muhammad, Suri Fareed, Saleem Shafaq, Qureshi Adnan

A Novel Imaging Biomarker to Make Precise Outcome Predictions for Patients with Acute Ischemic Stroke

Mallavarapu Monica, Kim Hyun Woo, Iyyangar Ananya, Salazar-marioni Sergio, Yoo Albert, Giancardo Luca, Sheth Sunil, Jeevarajan Jerome

More abstracts from these authors:
Multimodal MRI sequences are vital for the diagnosis of Vertebrobasilar Artery Dissection

Nakayama Yoshitaka, Mitsumura Hidetaka, Iguchi Yasuyuki, Kida Hiroyuki, Maku Takahiro, Nakada Ryoji, Kitagawa Tomomichi, Takatsu Hiroki, Komatsu Teppei, Sakuta Kenichi, Sakai Kenichiro

Lupus Anticoagulant Is Associated With Acute Recurrence in Cardiogenic Embolic Stroke in Older Patients

Kida Hiroyuki, Iguchi Yasuyuki, Sakai Kenichiro, Komatsu Teppei, Okumura Motohiro, Nakada Ryoji, Kitagawa Tomomichi, Takatsu Hiroki, Sakuta Kenichi, Mitsumura Hidetaka

You have to be authorized to contact abstract author. Please, Login
Not Available

Readers' Comments

We encourage you to enter the discussion by posting your comments and questions below.

Presenters will be notified of your post so that they can respond as appropriate.

This discussion platform is provided to foster engagement, and simulate conversation and knowledge sharing.

 

You have to be authorized to post a comment. Please, Login or Signup.


   Rate this abstract  (Maximum characters: 500)